Achilles Therapeutics plc (NASDAQ:ACHL) Sees Large Decrease in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 8,400 shares, a decrease of 56.3% from the July 31st total of 19,200 shares. Based on an average daily volume of 51,600 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the company’s shares are short sold.

Achilles Therapeutics Stock Performance

Shares of ACHL stock opened at $0.74 on Friday. Achilles Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $1.76. The firm has a market cap of $30.26 million, a P/E ratio of -0.46 and a beta of 1.32. The business’s 50 day moving average price is $0.80 and its 200-day moving average price is $0.94.

Achilles Therapeutics (NASDAQ:ACHL) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.41) EPS for the quarter, hitting analysts’ consensus estimates of ($0.41). As a group, equities analysts predict that Achilles Therapeutics will post -1.26 EPS for the current year.

Institutional Investors Weigh In On Achilles Therapeutics

Large investors have recently modified their holdings of the stock. Acadian Asset Management LLC bought a new stake in Achilles Therapeutics during the 1st quarter valued at approximately $350,000. Vestal Point Capital LP purchased a new position in shares of Achilles Therapeutics in the 4th quarter valued at approximately $96,000. Ikarian Capital LLC bought a new stake in shares of Achilles Therapeutics during the first quarter valued at approximately $1,804,000. XTX Topco Ltd grew its stake in Achilles Therapeutics by 239.4% in the second quarter. XTX Topco Ltd now owns 51,660 shares of the company’s stock worth $42,000 after purchasing an additional 36,441 shares during the period. Finally, StemPoint Capital LP bought a new position in Achilles Therapeutics in the first quarter worth $1,732,000. Institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.